CD274 and non-small cell lung carcinoma: Our previous work suggested that the expression of PD-L1 of pre-treatment tumors correlated with the degree of pathological regression in the 29 NSCLC patients when assessed by the CST anti-PD-L1 antibody (13684S)6.